Ryoo Byung-Hwan – CEO, Yungjin – South Korea
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
Yungjin Pharm. Co., Ltd was established in 1952, has been playing a major role as a forerunner in the Korean pharmaceutical industry for half a century. With the corporate mission of “To relieve the suffering of mankind from diseases with our innovative, effective and safe pharmaceutical products”, Yungjin has contributed to human health not only within Korea, but also through global expansion. As a result, Yungjin has received a total of 25 awards including the President’s Award for Superior Product Development, the Prime Minister’s Award, several Industry Awards, and many more. These accomplishments demonstrate Yungjin’s sustainability and commitment to the development of innovative products and business excellence in both overseas and domestic segments.
Contact Details:
451-20, Cheonho-dong,
Gangdong-gu,
Seoul, Korea
Tel : 82 2 2041 8200
Fax : 82 2 4630 9544
The CEO of Yungjin, a leading Korean pharma company, talks about the revitalization of the company he has overseen since being appointed in 2010. To begin, could you please…
A roundup of some of the biggest stories from South Korean healthcare and pharma, including the government’s continuing standoff with doctors over medical reform plans; Merck’s plans for a new…
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
See our Cookie Privacy Policy Here
